Botulinum toxin type A (BOTOX) for treatment of migraine.

Abstract

An open-label study and 2 double-blind, placebo-controlled studies have provided supporting evidence of botulinum toxin type A (BTX-A) as an effective, well-tolerated treatment for migraine. Observed durations of benefit were consistent with known properties of BTX-A. Findings suggest that response may vary by features of preinjection headaches, such as migraine frequency. The precise mechanism by which BTX-A provides pain relief is hypothesized to be related not only to acetylcholine inhibition but also to a blocking action on the parasympathetic nervous system. Additional studies that control factors likely to be related to response may lead to better understanding of the BTX-A effect on migraine and an optimal treatment protocol.

• Authors: W J Binder, M F Brin, A Blitzer, J M Pogoda
• Journal: Seminars in cutaneous medicine and surgery (Semin Cutan Med Surg) Vol. 20 Issue 2 Pg. 93-100 (Jun 2001) ISSN: 1085-5629 [Print] United States
• PMID: 11474749 (Publication Type: Journal Article, Review)

Chemical References

• Neuromuscular Agents
• Botulinum Toxins, Type A

Topics

• Adult
• Botulinum Toxins, Type A (pharmacology, therapeutic use)
• Clinical Trials as Topic
• Double-Blind Method
• Female
• Humans
• Injections
• Male
• Middle Aged
• Migraine Disorders (drug therapy, etiology)
• Neuromuscular Agents (pharmacology, therapeutic use)